AUPH

Over the past six months, Aurinia's stock has been impacted by several events. The company reported strong financial results for both full year 2025 and Q1 2026, with increased revenue and earnings per share. Aurinia announced a definitive agreement to acquire Kezar Life Sciences to expand its autoimmune and oncology pipeline. There was a leadership transition, with Kevin Tang appointed CEO, Ryan Cole COO, and Michael Hearne CFO. The company has been actively repurchasing shares, with 2.5 million shares repurchased in Q1 2026. As of May 8, 2026, the stock closed at $15.23, with a 52-week high of $16.88 and a low of $7.29.